Journal of Applied Physiology, Vol 73, Issue 1 346-353, Copyright © 1992 by American Physiological Society

ARTICLES

Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease

W. R. Hiatt, E. E. Wolfel, J. G. Regensteiner and E. P. Brass
Department of Medicine, University of Colorado School of Medicine, Denver 80262.

Patients with peripheral arterial disease (PAD) have abnormalities of carnitine metabolism that may contribute to their functional impairment. To test the hypothesis that muscle acylcarnitine generation (intermediates in oxidative metabolism) in patients with PAD provides a marker of the muscle dysfunction, 10 patients with unilateral PAD and 6 age-matched control subjects were studied at rest, and the patients were studied during exercise. At rest, biopsies of the gastrocnemius muscle in the patients' nonsymptomatic leg revealed a normal carnitine pool and lactate content compared with control subjects. In contrast, the patients' diseased leg had higher contents of lactate and long-chain acylcarnitines than controls. The muscle short-chain acylcarnitine content in the patients' diseased leg at rest was inversely correlated with peak exercise performance (r = -0.75, P less than 0.05). With graded treadmill exercise, only patients who exceeded their individual lactate threshold had an increase in muscle short-chain acylcarnitine content in the nonsymptomatic leg, which was identical to the muscle carnitine response in normal subjects. In the patients' diseased leg, muscle short-chain acylcarnitine content increased with exercise from 440 +/- 130 to 900 +/- 200 (SE) nmol/g (P less than 0.05). In contrast to the nonsymptomatic leg, there was no increase in muscle lactate content in the diseased leg with exercise, and the change in muscle carnitine metabolism was correlated with exercise duration (r = 0.82, P less than 0.01) and not with the lactate threshold. We conclude that energy metabolism in ischemic muscle of patients with PAD is characterized by the accumulation of acylcarnitines.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				G. M. Andreozzi, A. Leone, R. Laudani, R. Martin, G. Deinit, and V. Cataldi Levo-Propionyl-Carnitine Improves the Effectiveness of Supervised Physical Training on the Absolute Claudication Distance in Patients With Intermittent Claudication Angiology, March 1, 2008; 59(1): 84 - 89. [Abstract] [PDF]

				I. I. Pipinos, A. R. Judge, J. T. Selsby, Zhen Zhu, S. A. Swanson, A. A. Nella, and S. L. Dodd The Myopathy of Peripheral Arterial Occlusive Disease: Part 1. Functional and Histomorphological Changes and Evidence for Mitochondrial Dysfunction Vascular and Endovascular Surgery, January 1, 2008; 41(6): 481 - 489. [Abstract] [PDF]

				E. P Brass, W. R Hiatt, and S. Green Skeletal muscle metabolic changes in peripheral arterial disease contribute to exercise intolerance: a point-counterpoint discussion Vascular Medicine, November 1, 2004; 9(4): 293 - 301. [Abstract] [PDF]

				D. P. Faxon, V. Fuster, P. Libby, J. A. Beckman, W. R. Hiatt, R. W. Thompson, J. N. Topper, B. H. Annex, J. H. Rundback, R. P. Fabunmi, et al. Atherosclerotic Vascular Disease Conference: Writing Group III: Pathophysiology Circulation, June 1, 2004; 109(21): 2617 - 2625. [Full Text] [PDF]

				M. R Nehler, M. M McDermott, D. Treat-Jacobson, I. Chetter, and J. G Regensteiner Functional outcomes and quality of life in peripheral arterial disease: current status Vascular Medicine, May 1, 2003; 8(2): 115 - 126. [Abstract] [PDF]

				S. M Dean Pharmacologic treatment for intermittent claudication Vascular Medicine, November 1, 2002; 7(4): 301 - 309. [Abstract] [PDF]

				M. Condorelli and G. Brevetti Intermittent claudication: an historical perspective Eur. Heart J. Suppl., March 1, 2002; 4(suppl_B): B2 - B7. [Abstract] [PDF]

				W. R. Hiatt Medical Treatment of Peripheral Arterial Disease and Claudication N. Engl. J. Med., May 24, 2001; 344(21): 1608 - 1621. [Full Text] [PDF]

				E. P. Brass, W. R. Hiatt, A. W. Gardner, and C. L. Hoppel Decreased NADH dehydrogenase and ubiquinol-cytochrome c oxidoreductase in peripheral arterial disease Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H603 - H609. [Abstract] [Full Text] [PDF]

				E. P Brass, H. Wang, and W. R Hiatt Multiple skeletal muscle mitochondrial DNA deletions in patients with unilateral peripheral arterial disease Vascular Medicine, November 1, 2000; 5(4): 225 - 230. [Abstract] [PDF]

				E. P Brass and W. R Hiatt Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease Vascular Medicine, February 1, 2000; 5(1): 55 - 59. [Abstract] [PDF]

				G. Brevetti, C. Diehm, D. Lambert, and on behalf of the Study Investigators European multicenter study on propionyl-L-carnitine in intermittent claudication J. Am. Coll. Cardiol., November 1, 1999; 34(5): 1618 - 1624. [Abstract] [Full Text] [PDF]

				T. A. Bauer, J. G. Regensteiner, E. P. Brass, and W. R. Hiatt Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease J Appl Physiol, August 1, 1999; 87(2): 809 - 816. [Abstract] [Full Text] [PDF]

				H. K. Bhat, W. R. Hiatt, C. L. Hoppel, and E. P. Brass Skeletal Muscle Mitochondrial DNA Injury in Patients With Unilateral Peripheral Arterial Disease Circulation, February 16, 1999; 99(6): 807 - 812. [Abstract] [Full Text] [PDF]

				E. P. Brass and W. R. Hiatt The Role of Carnitine and Carnitine Supplementation During Exercise in Man and in Individuals with Special Needs J. Am. Coll. Nutr., June 1, 1998; 17(3): 207 - 215. [Abstract] [Full Text] [PDF]

				G. Brevetti, F. di Lisa, S. Perna, R. Menabo, R. Barbato, V. Domenico Martone, and N. Siliprandi Carnitine-Related Alterations in Patients With Intermittent Claudication : Indication for a Focused Carnitine Therapy Circulation, May 1, 1996; 93(9): 1685 - 1689. [Abstract] [Full Text]